Graves Orbitopathy Market: By Drug Class (Iodine and Iodides, Ionic Inhibitors, Radioactive Iodine, Beta Blockers, Thioamides and Corticosteroids), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Others), and by Geography

Graves Orbitopathy Market size was valued at USD x million in 2022, growing at a significant CAGR of x% from 2023-2029. Graves ophthalmopathy is also called thyroid-associated orbitopathy (TAO) and thyroid eye disease (TED), Graves orbitopathy (GO) is an autoimmune inflammatory disorder of the tissues of periorbital and orbit that is characterized by the retraction of the upper eyelid, lagging, swelling, and redness of lid, bulging of eyes and conjunctivitis. Most commonly occurs in individuals having Graves disease, and less commonly in individuals having Hashimoto's thyroiditis, or in people with euthyroid. It is a part of the systemic process of variable expression in skin, thyroid, and eyes that is caused by the autoantibodies that bind to the tissues of these organs. Autoantibodies target the fibroblasts in the eye muscles and fibroblasts can be differentiated into the fat cells (adipocytes). Muscles and fat cells expand and get inflammation. As per Wickham's study in England, in 2016, Graves disease is accounted for 0.5 cases per 1000 persons, with a high incidence rate in people aged 40 to 60. Graves disease is the high prevalent autoimmune disorder in the U.S. after Hashimoto's thyroiditis. In 2016, as per a research study of PREGO (presentation of Graves orbitopathy), the incidence of Graves orbitopathy in Europe was 10-30/10,000 humans annually. However, the severity and the incidence of Graves disease in Europe was observed to decline to 2.10/10,000/year. Iodine-131 is used in radioactive iodine ablation (RIA) to remove a whole or a part of the thyroid gland, which results in preventing the excessive production of thyroid hormone. Subtotal thyroidectomy used for the removal of the thyroid gland is the most invasive treatment option.

Key Developments:
In September 2014, Avalon Ventures and GlaxoSmithKline plc launced two new companies with USD10 Mn each in series a financing and R&D support companies including Silarus Therapeutics- developing treatments for anaemia and iron overload disorders and Thyritope Biosciences- developing treatments for graves orbitopathy